Clinical Trials Logo

Clinical Trial Summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder.

Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

NCT number NCT02836756
Study type Interventional
Source Centre hospitalier de l'Université de Montréal (CHUM)
Status Not yet recruiting
Phase Phase 2
Start date October 2016

See also
  Status Clinical Trial Phase
Recruiting NCT03318081 - The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction N/A
Completed NCT03221283 - The Application of Music Therapy in Female Amphetamine Use Disorder N/A
Withdrawn NCT02952196 - Cannabioids as a New Intervention for Amphetamine Dependence Phase 2
Completed NCT02285556 - The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus N/A
Recruiting NCT02713815 - Novel Intervention for Amphetamine-type Stimulants Addiction N/A
Completed NCT00713479 - An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers Phase 1
Not yet recruiting NCT02950376 - The Novel Addiction Assessment Study in Synthetic Drugs Addiction N/A